Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Forbes

Showing results (261-270 of 309) with videos related to

Pageof 31
Sort By:
Lancet (London, England)|May 11, 1996
Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study GroupC Hürny, J Bernhard, A S Coates, et al.
Trials|October 8, 2011
Recruiting South Asians to a lifestyle intervention trial: experiences and lessons from PODOSA (Prevention of Diabetes & Obesity in South Asians)Anne Douglas, Raj S Bhopal, Ruby Bhopal, et al.
Lancet (London, England)|December 22, 2015
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trialJohn F Forbes, Ivana Sestak, Anthony Howell, et al.
Stroke|April 18, 2020
Association Between Walking Pace and Stroke Incidence: Findings From the UK Biobank Prospective Cohort StudySara Hayes, John F Forbes, Carlos Celis-Morales, et al.
British Journal of Cancer|September 23, 1998
Factors affecting baseline quality of life in two international adjuvant breast cancer trials. International Breast Cancer Study Group (IBCSG)J Bernhard, C Hürny, A S Coates, et al.
The Lancet. Oncology|June 21, 2011
Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen typesSherene Loi, W Fraser Symmans, John M S Bartlett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VIIA Wallgren, M Bonetti, R D Gelber, et al.
The New England Journal of Medicine|December 31, 2005
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer, Beat Thürlimann, Aparna Keshaviah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2007
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trialHenning Mouridsen, Aparna Keshaviah, Alan S Coates, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2005
Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93, Carl-Magnus Rudenstam, David Zahrieh, et al.
Pageof 31

Showing results (261-270 of 309) with videos related to

Sort By:
Pageof 31
Lancet (London, England)|May 11, 1996
Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study GroupC Hürny, J Bernhard, A S Coates, et al.
Trials|October 8, 2011
Recruiting South Asians to a lifestyle intervention trial: experiences and lessons from PODOSA (Prevention of Diabetes & Obesity in South Asians)Anne Douglas, Raj S Bhopal, Ruby Bhopal, et al.
Lancet (London, England)|December 22, 2015
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trialJohn F Forbes, Ivana Sestak, Anthony Howell, et al.
Stroke|April 18, 2020
Association Between Walking Pace and Stroke Incidence: Findings From the UK Biobank Prospective Cohort StudySara Hayes, John F Forbes, Carlos Celis-Morales, et al.
British Journal of Cancer|September 23, 1998
Factors affecting baseline quality of life in two international adjuvant breast cancer trials. International Breast Cancer Study Group (IBCSG)J Bernhard, C Hürny, A S Coates, et al.
The Lancet. Oncology|June 21, 2011
Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen typesSherene Loi, W Fraser Symmans, John M S Bartlett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VIIA Wallgren, M Bonetti, R D Gelber, et al.
The New England Journal of Medicine|December 31, 2005
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer, Beat Thürlimann, Aparna Keshaviah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2007
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trialHenning Mouridsen, Aparna Keshaviah, Alan S Coates, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2005
Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93, Carl-Magnus Rudenstam, David Zahrieh, et al.
Pageof 31